+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID07106710

Study of Autologous Stem Cell Transplantation with BCMA CAR-T and GPRC5DCD3 Bispecific Antibody Maintenance in Ultra-High-Risk Multiple Myeloma Patients Eligible for Transplant

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-10-27

30

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a treatment approach for patients with newly diagnosed ultra-high-risk multiple myeloma who are eligible for stem cell transplantation. This phase II, single-arm study investigates the combination of autologous stem cell transplantation ASCT with BCMA CAR-T cell therapy, followed by maintenance treatment using a GPRC5DCD3 bispecific antibody. The goal is to assess the effectiveness and safety of this combined therapy in this high-risk patient group. Participants will first complete up to four cycles of standard induction therapy before screening. Those who qualify will undergo ASCT with conditioning, followed by a BCMA CAR-T cell infusion three days after transplantation. Starting three months after the CAR-T infusion, patients will begin maintenance therapy with GPRC5DCD3 bispecific antibodies given every four weeks at a dose of 54 micrograms per kilogram. Patients achieving stringent complete response sCR and sustained minimal residual disease MRD negativity for at least 12 months may enter an observation phase or continue maintenance for 24 months. Those who lose response during observation will resume maintenance, while patients without sCR and sustained MRD negativity continue maintenance until disease progression or unacceptable toxicity. During the study, participants will be assessed for MRD negativity rates and sustained MRD-negative status for up to two years. Researchers will also monitor safety, tolerability, complete response rates, progression-free survival for up to three years, and overall survival for up to five years. Patients will be closely followed with evaluations of disease status and treatment responses throughout the treatment and maintenance phases, helping to understand the long-term outcomes of this treatment combination.

CONDITIONS

Brief Title

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Research Team

G

Gang An, PhD&MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here